ScreenPoint Medical's Transpara software will be tested in a $16 million randomized controlled trial focusing on AI’s impact on early breast cancer detection.
The study, known as the PRISM Trial (Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography), is funded by the Patient-Centered Outcomes Research Institute and co-led by the University of California, Los Angeles (UCLA) and the University of California, Davis (UCD). It is the first large-scale trial of AI in breast cancer screening in the U.S. and will include hundreds of thousands of mammograms interpreted at academic medical centers and breast imaging facilities in California, Florida, Massachusetts, Washington, and Wisconsin, the company said.
The research builds on ScreenPoint’s collaboration with UCLA, the company noted. Clinical workflow integration will be provided by Aidoc’s aiOS platform, ScreenPoint added.
